These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 921315)

  • 1. Cystinotic rickets treated with vitamin D metabolites.
    Etches P; Pickering D; Smith R
    Arch Dis Child; 1977 Aug; 52(8):661-4. PubMed ID: 921315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of rickets caused by infantile cystinosis using 1 alpha-hydroxyvitamin D].
    Betend B; Chatelain P; David L; François R
    Arch Fr Pediatr; 1982 Oct; 39(8):615-8. PubMed ID: 7159161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of pseudovitamin D deficiency-like rickets in an infant treated with 1,25-dihydroxycholecalciferol. Preliminary note.
    Vecchio F; Carnevale F; Paganetti G; di Bitonto G; Marinelli G
    J Inherit Metab Dis; 1978; 1(4):183-5. PubMed ID: 117256
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of the rickets of cystinosis with 1-alpha-hydroxycholecalciferol.
    Gertner JM; Brenton DP; Dent CE; Domenech M
    Calcif Tissue Res; 1977 May; 22 Suppl():63-7. PubMed ID: 912591
    [No Abstract]   [Full Text] [Related]  

  • 5. 1,25-dihydroxyvitamin D3 and 1, alpha-hydroxyvitamin D3 in children: biologic and therapeutic effects in nutritional rickets and different types of vitamin D resistance.
    Balsan S; Garabedian M; Sorgniard R; Holick MF; Deluca HF
    Pediatr Res; 1975 Jul; 9(7):586-93. PubMed ID: 169507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1,25-Dihydroxyvitamin D3 in childhood hepatic osteodystrophy.
    Heubi JE; Tsang RC; Steichen JJ; Chan GM; Chen IW; DeLuca HF
    J Pediatr; 1979 Jun; 94(6):977-82. PubMed ID: 448553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New developments in pharmacology of vitamin D.
    Med Lett Drugs Ther; 1974 Feb; 16(3):15-6. PubMed ID: 4358446
    [No Abstract]   [Full Text] [Related]  

  • 8. [Therapy with vitamin D and D-metabolites].
    Flury W; Haldimann B
    Schweiz Med Wochenschr; 1981 Feb; 111(9):314-21. PubMed ID: 6261326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Recommended for use in various bone diseases: therapy with a vitamin D metabolite].
    MMW Munch Med Wochenschr; 1979 Aug; 121(34):1062. PubMed ID: 114759
    [No Abstract]   [Full Text] [Related]  

  • 10. Resistance to vitamin D and parathyroid hormone.
    Moses AM
    N Engl J Med; 1978 Aug; 299(8):423-4. PubMed ID: 209328
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of 1,25(OH)2D3 and 24,25(OH)2D3 on experimental rickets.
    Kraft D; Offermann G; Steldinger R; Gawlik D
    Res Commun Chem Pathol Pharmacol; 1979 Dec; 26(3):571-80. PubMed ID: 523788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypophosphatemic rickets: effect of 1 alpha, 25-dihydroxyvitamin D3 on growth and mineral metabolism.
    Chan JC; Bartter FC
    Pediatrics; 1979 Oct; 64(4):488-95. PubMed ID: 492815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin D. Metabolism and mechanism of action.
    Olson EB; DeLuca HF
    World Rev Nutr Diet; 1973; 17():164-88. PubMed ID: 4348597
    [No Abstract]   [Full Text] [Related]  

  • 14. [Vitamin D-metabolism and rickets (author's transl)].
    Burmeister W
    Monatsschr Kinderheilkd (1902); 1979 Jul; 127(7):421-5. PubMed ID: 226875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. End-organ resistance to 1,25-dihydroxycholecalciferol.
    Liberman UA; Samuel R; Halabe A; Kauli R; Edelstein S; Weisman Y; Papapoulos SE; Clemens TL; Fraher LJ; O'Riordan JL
    Lancet; 1980 Mar; 1(8167):504-6. PubMed ID: 6102232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 25-Hydroxycholecalciferol. A comparative study in deficiency rickets and different types of resistant rickets.
    Balsan S; Garabedian M
    J Clin Invest; 1972 Apr; 51(4):749-59. PubMed ID: 4335443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proceedings: The use of metabolically-active derivatives of vitamin D in rickets and osteomalacia due to renal glomerular failure.
    Smith R; Henderson RG; Russell RG
    J Bone Joint Surg Br; 1975 May; 57(2):247-8. PubMed ID: 1141297
    [No Abstract]   [Full Text] [Related]  

  • 18. [Calcium phosphate metabolism during therapy with 1,25-dihydroxycholecalciferol [1,25 DHCC (Ro 21/5535)] in patients with advanced kidney insufficiency].
    Schulz W; Spiegel P; Gessler U; Delling G
    Verh Dtsch Ges Inn Med; 1978; (84):1297-301. PubMed ID: 741953
    [No Abstract]   [Full Text] [Related]  

  • 19. Actions of 1,25-dihydroxycholecalciferol in patients with hypophosphatemic, vitamin-D-resistant rickets.
    Brickman AS; Coburn JW; Kurokawa K; Bethune JE; Harrison HE; Norman AW
    N Engl J Med; 1973 Sep; 289(10):495-8. PubMed ID: 4353218
    [No Abstract]   [Full Text] [Related]  

  • 20. The metabolism of vitamin D; recent developments and their clinical relevance.
    Steendijk R
    Neth J Med; 1974; 17(3):131-9. PubMed ID: 4367820
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.